Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. insider filing reports that Bayview Legacy, LLC, an entity managed by K. Charles Janac, sold 100,000 shares of Arteris common stock on 10/06/2025 under a 10b5-1 trading plan. The sales were executed in multiple transactions at weighted-average price $13.1045, with trade prices ranging from $12.50 to $13.85. After the disposition, Bayview Legacy, LLC is reported to beneficially own 9,739,071 shares, and Janac is deemed to have voting and dispositive power as the manager. Janac also filed a separate Form 4 reporting the same sale in his individual capacity.
Arteris, Inc. director Antonio J. Viana reported insider sales on 10/06/2025. The filing shows a sale of 11,841 shares of common stock at a price of $14 and an additional disposal of 20,840 common shares. After these transactions the reporting person is listed as beneficially owning 184,620 shares indirectly through the Viana Family Trust. The sales were made under a pre-existing Rule 10b5-1 trading plan that the reporting person adopted on 06/10/2025, and the Form 4 was signed by an attorney-in-fact on 10/06/2025. The filing presents routine, planned insider disposals rather than unscheduled or ad-hoc trades.
Arteris, Inc. (AIP) submitted a Rule 144 notice proposing the sale of 50,000 common shares through Morgan Stanley Smith Barney LLC for an aggregate market value of $647,500. The notice lists the company's total outstanding shares as 42,649,917 and an approximate sale date of 10/08/2025. The shares were originally acquired from the issuer in a private transaction on 11/05/2013 and were paid for in cash. The filing also discloses multiple recent sales by related parties and 10b5-1 plans in the past three months, including transactions dated 08/05/2025, 09/02/2025, and 10/06/2025, with amounts ranging up to $1,310,450.00 in gross proceeds for a single sale.
Arteris, Inc. filing a Form 144 notifies a proposed sale of 6,421 common shares (acquired as restricted stock units) with an aggregate market value of $87,197.18, through Morgan Stanley Smith Barney LLC on or about 10/07/2025. The RSUs were recorded as acquired on 10/01/2025 and the filing lists previous sales by the same person totaling 30,538 shares during the prior three months, generating gross proceeds of $336,546.61. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 sales plans used for several prior transactions.
Insider sale summary: A Form 4 shows that Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), sold a total of 7,627 shares of common stock in two days, 10/02/2025 and 10/03/2025, to satisfy tax obligations arising from the release of restricted stock units and under a previously adopted trading plan. The reported weighted average sale prices ranged from $10.81 to $11.30 with the weighted averages disclosed as $10.9208 and $11.082.
After these dispositions, the reporting person beneficially owned 65,960 shares directly. One tranche of the sales was executed pursuant to a 10b5-1 trading plan adopted on 06/05/2025, and the filer states the sales served to cover tax liabilities from released restricted stock units.
Arteris, Inc. (AIP) reported insider transactions by its Chief Operating Officer. On 10/02/2025, the COO sold 1,885, 891, and 1,926 shares at $10.9208 per share, including shares sold to satisfy tax liabilities from restricted stock unit release. Additional sales under a Rule 10b5-1 trading plan adopted on March 12, 2025 included 19,060 shares at a weighted average price of $10.9908 on 10/02/2025, 1,554 shares at $11.0866 on 10/03/2025, and 17,200 shares at $12.6598 on 10/06/2025.
Following these transactions, the COO beneficially owned 343,885 shares directly.
Arteris (AIP) — Form 4 insider activity: President and CEO K. Charles Janac, who is also a Director and 10% Owner, reported open‑market sales on 10/02/2025 and 10/03/2025. The filing lists sales of 2,767, 1,613, and 2,767 shares at $10.9208, and a separate sale of 11,821 shares at a weighted average price of $11.0705 (with individual trades between $10.80 and $11.29).
One set of shares was sold to satisfy the reporting person’s tax liability from an RSU release, and another transaction was made under a Rule 10b5‑1 trading plan adopted on March 5, 2025. Following the reported transactions, direct holdings were shown as 167,514 shares. Indirect holdings were listed as 9,839,071 shares through Bayview Legacy, LLC and 56,252 shares held by the Charles and Lydia Janac Trust.
Insider sale to cover taxes by Arteris CFO. On 10/02/2025, Nicholas B. Hawkins, the company’s Vice President and Chief Financial Officer, reported three open-market sales of 3,887 shares of Arteris, Inc. (AIP) at an effective price of $10.9208 per share. The three disposals were for 891, 1,508 and 1,488 shares and reduced the reporting person’s direct holdings in stages from 103,007 shares to 100,011 shares following the transactions.
The filing states the shares were sold to satisfy the reporting person’s tax liability triggered by the release of restricted stock units. The Form 4 was signed by an attorney-in-fact on 10/06/2025. No derivative transactions or other types of securities were reported.
Arteris, Inc. director Joachim Kunkel reported receipt of 1,496 shares of common stock as fully vested restricted stock on 10/05/2025. The shares were issued as retainer fees elected in lieu of cash and the reporting person elected to defer receipt; the transaction price is reported as $0.00.
Following the transaction, the reporting person beneficially owns 67,818 shares. The Form 4 was signed by an attorney-in-fact on 10/06/2025 and indicates the filing is by one reporting person and that the reporting person is a director.
Arteris, Inc. reported a Form 144 notice for the proposed sale of 5,755 common shares with an aggregate market value of $63,189.90, showing an approximate sale date of 10/06/2025 on NASDAQ. The securities were originally acquired on 06/16/2014 in a private acquisition from the issuer and paid for in cash. The filing lists multiple recent dispositions by the related party, including several 10b5-1 sales and direct sales by K. CHARLES JANAC totalling sizeable proceeds in August–October 2025 (examples: $1,271,120.01 for 94,245 shares on 08/05/2025; $655,995.00 for 50,000 shares on 08/05/2025). The filing includes the required representation that the seller is not aware of undisclosed material adverse information.